After switching from a desktop to a laptop, I faced chaos with my setup, prompting me to experiment with different configurations. I finally achieved a clean and functional setup by incorporating a ...

Who doesn't love getting the latest tech for the holidays? It's the perfect time to unwind with some of your favorite games, after all. Whether you want to treat yourself or make that special gamer in ...

The new-for-2025 Alienware 16X Aurora gaming laptop is on sale today at a price that's lower than any Black Friday deal. You can pick up a well-specced laptop featuring an Intel Core Ultra 9 CPU and ...

A startup company backed by Donald Trump Jr.’s investment firm received a $620 million loan from the U.S. Department of Defense. Rumors circulated online in December 2025 that a startup company backed ...

Nearly 150 Denny’s restaurants are scheduled to close by the end of 2025, marking the largest retrenchment in the chain’s history and underscoring the pressures facing traditional full-service diners.

Rumors circulated online in December 2025 that a startup company backed by Donald Trump Jr.'s venture capital firm was granted a $620 million loan from the U.S. Department of Defense (DOD). ‼️‼️ ...

34-inch size is great for movies, gaming, and work Much better text sharpness than early OLEDs Fantastic gaming performance Simpler, more practical design than predecessor Great out-of-the-box image ...

Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal ...

Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Bluejay Therapeutics, a biotechnology startup making a ...

Bluejay Therapeutics, a biotechnology startup making a treatment for hepatitis D, is set to be acquired by rare disease drugmaker Mirum Pharmaceuticals in a deal that could be worth as much as $820 ...